— Know what they know.
Not Investment Advice

300039.SZ SHZ

Shanghai Kaibao Pharmaceutical CO.,Ltd
1W: +0.0% 1M: -2.8% 3M: +18.6% YTD: -18.8% 1Y: -19.9% 3Y: -18.3% 5Y: +14.0%
¥5.30 ($0.79)
+0.15 (+2.91%)
 
SHZ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 47 · ¥5.5B mcap · 916M float · 4.25% daily turnover
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap¥5.5B ($826.9M)
52W Range4.02-6.77
Volume24,652,260
Avg Volume38,987,651
Beta0.17
Dividend¥0.13
Analyst Ratings
No analyst coverage
Company Info
CEOYingbin Zhou
Employees1,197
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2010-01-08
Websitexykb.com
No. 88 Chengpu Road
Shanghai, SH 201401
CN
86 21 3757 2030
About Shanghai Kaibao Pharmaceutical CO.,Ltd

Shanghai Kaibao Pharmaceutical CO.,Ltd specializes in the research, development, manufacturing, and sale of modern Traditional Chinese Medicines, primarily operating within China. Its diverse product lineup features several key pharmaceutical solutions. These include: Tanreqing injection, which is extensively utilized for addressing conditions like pneumonia, acute and chronic bronchitis, and upper respiratory tract infections. Tanreqing capsules, formulated to reduce internal heat, detoxify the system, and clear phlegm. Tiopronin for injection, designed to enhance liver function for various acute and chronic hepatitis patients. Tiopronin enteric-coated tablets, prescribed as a supplementary therapy for managing chronic hepatitis. Xiongdan dropping pills, known for their efficacy in alleviating heat, calming the liver, and promoting improved vision. Established in 2000, the company's operations are based in Shanghai, China.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms